Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Mohamed Bakri Mohamed, Seán R Millar, Vitaliy Mykytiv, Rose McMorrow, Conan Donnelly, Paul M Walsh, Eamonn O'Leary, Nina Orfali, Philip Murphy, Paul V. Browne, John Quinn, Peter O'Gorman, Ruth Clifford, Ezzat El Hassadi, Oonagh Gilligan, Janusz Krawczyk, Michael E. O'Dwyer, Eva Szegezdi, Mary R Cahill

Blood (2021) 138 (Supplement 1): 1218.

https://doi.org/10.1182/blood-2021-149832

Published: 2021

Journal Articles

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Robert Henderson, MD, Mary R Cahill, MD, Philip Murphy, MD, Vitaliy Mykytiv, MD, John Quinn, MD PhD, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Andres Hernando, Grace Hirakata, Imelda Parker, Emma Kinsella, Grainne Gannon, Alessandro Natoni, PhD, Michael E O'Dwyer, MD

Blood (2018) 132 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2018-99-112375

Published: 2018

Journal Articles

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Cian McEllistrim, MD, Mary R Cahill, MD, Philip Murphy, PhD BPharm, Vitaliy Mykytiv, MD, John Quinn, Amanda Bray, Jessica Walsh, Elizabeth Lenihan, Tara Kenny, Grace Hirakata, Imelda Parker, Andres Hernando, Michael O'Dwyer, MD

Blood (2017) 130 (Supplement 1): 3163.

https://doi.org/10.1182/blood.V130.Suppl_1.3163.3163

Published: 2017

Journal Articles

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

Niamh Appleby, FRCPath, Fiona M Quinn, PhD, David O'Brien, FAMLs, Smyth Liam, MRCPI, Johanna Kelly, BSc, Imelda Parker, Kathleen Scott, PhD, Mary R Cahill, MB, FRCPath, Gerard Crotty, Helen Enright, MD FRCPI, FRCPath, Brian Hennessy, MD MRCPI, FRCPath, Andrew Hodgson, MBBS, BSc, FRCP, FRCPath, Maeve Leahy, FRCPath, Hilary M O'Leary, FRCPath, Michael E O'Dwyer, MD, Amjad Hayat, MBBS, MRCP, MRCPath, PhD, Elisabeth A. Vandenberghe, MB, MRCPI, MRCPath, PhD

Blood (2016) 128 (22): 3237.

https://doi.org/10.1182/blood.V128.22.3237.3237

Published: 2016

Journal Articles

ATRA-Induced Activation of the Autophagy Regulator Tfeb Regulates Myeloid Differentiation in Acute Promyelocytic Leukemia

Nina M. Orfali, MBBchBAO, Nigel P. Mongan, PhD, Mary R Cahill, MDFRCPath, Sharon L. McKenna, PhD, Lorraine J. Gudas, PhD

Blood (2014) 124 (21): 1057.

https://doi.org/10.1182/blood.V124.21.1057.1057

Published: 2014

Journal Articles

Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation

Loveena Rishi, Maura Hannon, Mara Salomè, Marie Hasemann, Anne-Katrine Frank, Joana Campos, Jennifer Timoney, Caitriona O’Connor, Mary R. Cahill, Bo Porse, Karen Keeshan

Blood (2014) 123 (15): 2389–2400.

https://doi.org/10.1182/blood-2013-07-511683

Published: 2014

Includes: Supplemental data

Journal Articles

Irish Hospitals Meet Proposed International Guidelines For Non-Hodgkin Lymphoma Management, But Areas For Improvement Remain

Rory Crotty, Maeve P Crowley, MB BCh BAO, Mary R Cahill, MD FRCPath, Brian R Healey Bird, MB, FRCP

Blood (2013) 122 (21): 5591.

https://doi.org/10.1182/blood.V122.21.5591.5591

Published: 2013

Journal Articles

Cigarette Smoking Is An Under Recognised Cause Of Macrocytosis

Maeve A O'Reilly, Claire M Buckley, Janas M Harrington, Susan O'Shea, Ivan J Perry, Mary R Cahill

Blood (2013) 122 (21): 4660.

https://doi.org/10.1182/blood.V122.21.4660.4660

Published: 2013

Journal Articles

Macrocytosis: A Metabolic Marker?

Maeve A O'Reilly, Janas M Harrington, Claire M Buckley, Susan O'Shea, Ivan J Perry, Mary R Cahill

Blood (2013) 122 (21): 4663.

https://doi.org/10.1182/blood.V122.21.4663.4663

Published: 2013

Journal Articles

Elucidation and Therapeutic Targeting Of The Molecular Mechanism Of TRIB2-Mediated Acute Myeloid Leukaemia

Fiona Lohan, Ciaran Forde, Mara Salome, Caitriona O'Connor, Fiona Bailey, Mary R Cahill, MD FRCPath, Ruud Delwel, Patrick Eyers, Patrick Kiely, Karen Keeshan

Blood (2013) 122 (21): 3792.

https://doi.org/10.1182/blood.V122.21.3792.3792

Published: 2013

Journal Articles

Elucidation and Therapeutic Targeting Of The Molecular Mechanism Of TRIB2-Mediated Acute Myeloid Leukaemia

Fiona Lohan, Ciaran Forde, Mara Salome, Caitriona O'Connor, Fiona Bailey, Mary R Cahill, MD FRCPath, Ruud Delwel, Patrick Eyers, Patrick Kiely, Karen Keeshan

Blood (2013) 122 (21): 3799.

https://doi.org/10.1182/blood.V122.21.3799.3799

Published: 2013

Journal Articles

Radiation Exposure From Diagnostic Imaging in Patients with Lymphoma - The Cost Of The Cure?

Maeve P Crowley, MB BCh BAO, Siobhan B O'Neill, MB BAO BCh, Damien C O'Neill, MB BAO BCh, Joesph A Eustace, MB BCh MHS, Brian R Healey Bird, MB, FRCP, Mary R Cahill, MD FRCPath, Michael M Maher, MD FRCSI FFRRCSI FRCR, Kevin N O' Regan, MB BCh BAO FFRRCSI., Derville M O'Shea, MB PhD FRCPATH

Blood (2013) 122 (21): 557.

https://doi.org/10.1182/blood.V122.21.557.557

Published: 2013

Journal Articles

Autophagy As a Target for Differentiation Therapy in Acute Myeloid Leukemia.

Nina M. Orfali, MBBchBAO, Tracey O'Donovan, PhD, Michelle Nyhan, PhD, Nigel P Mongan, PhD, Lorraine J Gudas, PhD, Mary R Cahill, MB FRCPath, Sharon McKenna, PhD

Blood (2012) 120 (21): 2464.

https://doi.org/10.1182/blood.V120.21.2464.2464

Published: 2012

Journal Articles

The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine.

Kevin R. Kelly, MD, Ronan T. Swords, M.D., Devalingam Mahalingam, M.D., Steffan T. Nawrocki, PhD, Ernest Medina, B.S., Sabrina Smith, Swaminathan Padmanabhan, MD, MBBS, Jeffrey Ecsedy, Mary R Cahill, FRCPI, FRCPath, Francis J. Giles, MB, MD, FRCPI, FRCPath, Jennifer S. Carew, Ph.D.

Blood (2009) 114 (22): 2087.

https://doi.org/10.1182/blood.V114.22.2087.2087

Published: 2009

Journal Articles

Phase 1 Clinical Trial of Prion-Filtered Red Cell Concentrates (pfRCC) in Patients Requiring Allogeneic Blood Transfusion.

Tracy Murphy, Mary R Cahill, Jim Fagan, Croxon Harry, Mohammed Khan, Oonagh Gilligan, Stephen McGrath, William G Murphy

Blood (2008) 112 (11): 994.

https://doi.org/10.1182/blood.V112.11.994.994

Published: 2008

NARROW

Examining the Usefulness of the Charlson Comorbidity Index to Predict Early Mortality in Patients with Acute Myeloid Leukaemia

Cybord-Dara Is a Highly Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Initial Efficacy Results of the 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Weekly CyborD-DARA Is a Safe and Effective Upfront Treatment for Newly Diagnosed Multiple Myeloma. Preliminary Results of the Early Phase 16-Bcni-001/Ctrial-IE (ICORG) 16-02 Study

Minimal Residual Disease (MRD) Status in FCR-Treated CLL Patients at the End of Treatment Influences Progression Free Survival (PFS), Results of the Ctrial-IE (ICORG) 07-01/ CLL Ireland Study, with Mutational Analysis Providing Additional Insight

ATRA-Induced Activation of the Autophagy Regulator Tfeb Regulates Myeloid Differentiation in Acute Promyelocytic Leukemia

Regulation of Trib2 by an E2F1-C/EBPα feedback loop in AML cell proliferation

Irish Hospitals Meet Proposed International Guidelines For Non-Hodgkin Lymphoma Management, But Areas For Improvement Remain

Cigarette Smoking Is An Under Recognised Cause Of Macrocytosis

Macrocytosis: A Metabolic Marker?

Elucidation and Therapeutic Targeting Of The Molecular Mechanism Of TRIB2-Mediated Acute Myeloid Leukaemia

Elucidation and Therapeutic Targeting Of The Molecular Mechanism Of TRIB2-Mediated Acute Myeloid Leukaemia

Radiation Exposure From Diagnostic Imaging in Patients with Lymphoma - The Cost Of The Cure?

Autophagy As a Target for Differentiation Therapy in Acute Myeloid Leukemia.

The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine.

Phase 1 Clinical Trial of Prion-Filtered Red Cell Concentrates (pfRCC) in Patients Requiring Allogeneic Blood Transfusion.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only